Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.

MLA

Ansén, Sascha, et al. “Osteoblastic Response in Patients with Non-Small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 5, no. 3, Mar. 2010, pp. 407–09. EBSCOhost, https://doi.org/10.1097/JTO.0b013e3181cf32aa.

APA

Ansén, S., Bangard, C., Querings, S., Gabler, F., Scheffler, M., Seidel, D., Saal, B., Zander, T., Nogová, L., Töpelt, K., Markert, E., Stoelben, E., Ernestus, K., Thomas, R. K., & Wolf, J. (2010). Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 5(3), 407–409. https://doi.org/10.1097/JTO.0b013e3181cf32aa

Chicago

Ansén, Sascha, Christopher Bangard, Silvia Querings, Franziska Gabler, Matthias Scheffler, Daniela Seidel, Beate Saal, et al. 2010. “Osteoblastic Response in Patients with Non-Small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 5 (3): 407–9. doi:10.1097/JTO.0b013e3181cf32aa.